ClinicalTrials.gg
CompletedNCT01599650BRIGHTERUpdated Nov 10, 2016Results posted

Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion

A Phase 3 interventional study of Ranibizumab and Laser in Branch Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 82 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
455
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies testing ranibizumab in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. Ranibizumab · Retinal Vein Occlusion.

Enrollment
2nd of 47
455 · median 56
Started
2012
with 4 others
Phase 3
13 of 47
none open now
Registered
26th of 47
by date
Lead sponsor
9 of 47
Novartis Pharmaceuticals

Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, this one is the 2nd largest by enrollment, is one of 5 that started in 2012, is one of 13 in phase 3, and was the 26th registered.

Retinal Vein Occlusion

289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

None of the 47 studies testing ranibizumab in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 47 studies testing ranibizumab in Retinal Vein Occlusion as a file.
02

Study summary

This study will generate comparative data for 0.5-mg ranibizumab using PRN dosing administered with or without adjunctive laser treatment versus laser photocoagulation (the current standard of care) up to Month 6 in patients with visual impairment due to ME secondary to BRVO. Additionally the results of this study will provide long-term (24-month) safety and efficacy data for ranibizumab, administered with or without adjunctive laser treatment in this indication.

03

Conditions studied

  • Branch Retinal Vein Occlusion

Keywords

  • Macular Edema, Branch Retinal Vein Occlusion, visual impairment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any study assessment is performed
  • Diagnosis of visual impairment exclusively due to ME secondary to BRVO
  • BCVA score at Screening and Baseline between 73 and 19 letters (ETDRS)

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing (lactating) women
  • Stroke or myocardial infarction less than 3 months before Screening
  • Uncontrolled blood pressure defined as systolic value of >160 mm Hg or diastolic value of >100 mm Hg at Screening or Baseline.
  • Any active periocular or ocular infection or inflammation at Screening or Baseline in either eye
  • Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months before Baseline in either eye
  • Neovascularization of the iris or neovascular glaucoma in the study eye
  • Use of any systemic antivascular endothelial growth factor (anti-VEGF) drugs within 6 months before Baseline
  • Panretinal laser photocoagulation within 3 months before Baseline or anticipated or scheduled within the next 3 months following Baseline in the study eye
  • Focal or grid laser photocoagulation within 4 months before Baseline in the study eye
  • Use of intra- or periocular (including sub-Tenon) within 3 months before Screening in the study eye
  • Any use of intraocular corticosteroid implants (eg, dexamethasone [Ozurdex®], fluocinolone acetonide [Iluvien®]) in the study eye
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
455 participants (actual)

Study arms

  • Experimental
    1-ranibizumab monotherapy

    Ranibizumab 0.5 mg

    Drug: Ranibizumab

  • Experimental
    2-ranibizumab with laser

    Ranibizumab 0.5 mg + laser

    Drug: Ranibizumab · Procedure: Laser

  • Active comparator
    3-laser monotherapy

    Laser monotherapy with Ranibizumab 0.5 mg from Month 6

    Procedure: Laser

Interventions

  • Also known as: Lucentis

  • ProcedureLaser

    laser photocoagulation

06

What researchers measure

Primary outcomes

  1. Mean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO)

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 6 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and assessed by an ANOVA model.

    Time frame: Baseline, 6 Months

Secondary outcomes

  1. The Mean Average Change in Visual Acuity From Month 1 Through Month 24 Compared to Baseline

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. (A positive average change from baseline of BCVA indicates improvement): Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 24. Then, mean average change is calculated as the average of average changes across all patients.

    Time frame: Baseline, 24 Months

  2. Number of Ranibizumab Treatments From Day 1 to Month 23 by Treatment Group

    Number of injections provided to the patients during the 23 month period and conducted within FAS with LOCF and observed data.

    Time frame: Day 1 through Month 23

  3. Mean Average Change in Visual Acuity (BCVA Letters) From Month 1 Through Month 6

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters.(A positive average change from baseline of BCVA indicates improvement): Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 6. Then, mean average change is calculated as the average of average changes across all patients.

    Time frame: From Baseline through Month 6

  4. The Mean Change in Visual Acuity BCVA (Letters) From Baseline at Month 12 and Month 24

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and Month 24 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and were assessed by an ANOVA model.

    Time frame: Baseline, Month 12 and Month 24

  5. The Percent of Patients With a Visual Acuity Gain of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline up to Month 6 and Month 24, by Visit

    BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 6 \& Month 24 as compared with baseline, was assessed by an ANOVA model. Endpoints related to the proportion of patients with BCVA letter gain or loss from Baseline was analyzed via stratified Cochran-Mantel-Haenszel test with stratification based on baseline BCVA (baseline BCVA less than or equal to 39, 40 to 59, greater than or equal to 60 letters, treatment groups).

    Time frame: Baseline, Month 6 and Month 24

  6. Number of Patients With a BCVA Improvement vs Baseline or Achieving Greater Than or Equal to 73 Letters at Month 6 in the Study Eye

    Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and Month 6 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 6 indicates a positive outcome.

    Time frame: Month 6

  7. Number of Patients With a BCVA Improvement vs Baseline or Achieved Greater Than or Equal to 73 Letters at Month 24 in the Study Eye

    Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and Month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 24 indicates a positive outcome.

    Time frame: Month 24

  8. The Mean Change in Central Reading Center-assessed Central Subfield Thickness From Month 12 and Month 24 vs. Baseline by Treatment Arm

    Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation. Stratification was done based on categories of baseline best corrected visual acuity \& analysis was based on analysis of variance (ANOVA)

    Time frame: Month 12 and Month 24

  9. The Mean Change in Patient Reported Outcomes in NEI-VFQ-25 Score (Composite Score and Subscales) at Month 6 and Month 24 Compared to Baseline

    The survey consists of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.

    Time frame: Months 6 and 24

  10. BCVA (Letters) Mean Average Change From First Ranibizumab Treatment to Month 24 in the Study Eye for Patients Randomized to the Laser Monotherapy Arm

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 24 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and assessed by an ANOVA model.

    Time frame: Month 24

07

Results

Posted Nov 10, 2016

Participant flow

Participant flow — Overall Study
Milestone1-ranibizumab Monotherapy2-ranibizumab With Laser3-laser Monotherapy
Started18318092
Completed 6 mos17417080
Completed16115465
Not completed222627
Withdrew: Administrative issue101
Withdrew: Physician decision207
Withdrew: Protocol violation030
Withdrew: Death212
Withdrew: Lost to follow-up333
Withdrew: Withdrawal by subject111110
Withdrew: Adverse event384

Outcome measures

PrimaryMean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO)

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 6 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and assessed by an ANOVA model.

Time frame:
Baseline, 6 Months
Reported as:
Mean · letters
Mean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO)
letters1-ranibizumab Monotherapy2-ranibizumab With Laser3-laser Monotherapy
Baseline59.5 ± 11.7856.6 ± 13.1956.8 ± 13.86
Month 674.3 ± 12.2771.4 ± 14.4362.8 ± 14.08
Change from Baseline atMonth 614.8 ± 10.7014.8 ± 11.136.0 ± 14.27
Statistical analysis
  • 1-ranibizumab Monotherapy vs 3-laser Monotherapy · ANOVA · p = <0.0001 · Difference in ls mean: 10.0 · 95% CI 7.3 to 12.8
  • 2-ranibizumab With Laser vs 3-laser Monotherapy · ANOVA · p = <0.0001 · Difference in ls means: 8.7 · 95% CI 5.8 to 11.6
SecondaryThe Mean Average Change in Visual Acuity From Month 1 Through Month 24 Compared to Baseline

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. (A positive average change from baseline of BCVA indicates improvement): Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 24. Then, mean average change is calculated as the average of average changes across all patients.

Time frame:
Baseline, 24 Months
Reported as:
Mean · letters
The Mean Average Change in Visual Acuity From Month 1 Through Month 24 Compared to Baseline
letters1-ranibizumab Monotherapy2-ranibizumab With Laser3-laser Monotherapy
Baseline59.5 ± 11.7856.6 ± 13.1956.8 ± 13.86
Average Month 1 toMonth 2474.5 ± 12.1172.0 ± 13.5665.9 ± 13.24
Change from Baseline15.0 ± 10.8615.4 ± 10.769.1 ± 13.49
SecondaryNumber of Ranibizumab Treatments From Day 1 to Month 23 by Treatment Group

Number of injections provided to the patients during the 23 month period and conducted within FAS with LOCF and observed data.

Time frame:
Day 1 through Month 23
Reported as:
Mean · treatments
Number of Ranibizumab Treatments From Day 1 to Month 23 by Treatment Group
treatments1-ranibizumab Monotherapy2-ranibizumab With Laser
Number of Ranibizumab Treatments From Day 1 to Month 23 by Treatment Group11.4 ± 5.7611.3 ± 6.03
SecondaryMean Average Change in Visual Acuity (BCVA Letters) From Month 1 Through Month 6

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters.(A positive average change from baseline of BCVA indicates improvement): Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 6. Then, mean average change is calculated as the average of average changes across all patients.

Time frame:
From Baseline through Month 6
Reported as:
Mean · letters
Mean Average Change in Visual Acuity (BCVA Letters) From Month 1 Through Month 6
letters1-ranibizumab Monotherapy2-ranibizumab With Laser3-laser Monotherapy
Baseline59.5 ± 11.7856.6 ± 13.1956.8 ± 13.86
Average Month 1 to Month 672.7 ± 11.4969.7 ± 13.3861.7 ± 12.66
Change from Baseline13.2 ± 9.6013.2 ± 9.894.8 ± 11.69
SecondaryThe Mean Change in Visual Acuity BCVA (Letters) From Baseline at Month 12 and Month 24

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and Month 24 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and were assessed by an ANOVA model.

Time frame:
Baseline, Month 12 and Month 24
Reported as:
Mean · letters
The Mean Change in Visual Acuity BCVA (Letters) From Baseline at Month 12 and Month 24
letters1-ranibizumab Monotherapy2-ranibizumab With Laser3-laser Monotherapy
Baseline59.5 ± 11.7856.6 ± 13.1956.8 ± 13.86
Month 1274.9 ± 12.8772.3 ± 15.3166.8 ± 13.87
Change from baseline Month 1215.4 ± 12.2515.7 ± 13.1210.0 ± 14.33
Month 2475.0 ± 14.6573.9 ± 14.5968.4 ± 15.26
Change from baseline Month 2415.5 ± 13.9117.3 ± 12.6111.6 ± 16.09
SecondaryThe Percent of Patients With a Visual Acuity Gain of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline up to Month 6 and Month 24, by Visit

BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 6 \& Month 24 as compared with baseline, was assessed by an ANOVA model. Endpoints related to the proportion of patients with BCVA letter gain or loss from Baseline was analyzed via stratified Cochran-Mantel-Haenszel test with stratification based on baseline BCVA (baseline BCVA less than or equal to 39, 40 to 59, greater than or equal to 60 letters, treatment groups).

Time frame:
Baseline, Month 6 and Month 24
Reported as:
Number · percent patients gaining improvement
The Percent of Patients With a Visual Acuity Gain of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline up to Month 6 and Month 24, by Visit
percent patients gaining improvement1-ranibizumab Monotherapy2-ranibizumab With Laser3-laser Monotherapy
BCVA improvement of >= 1 lettermonth 693.396.163.3
BCVA improvement of >= 1 lettermonth 2489.493.877.8
BCVA improvement of >= 5 lettersmonth 686.188.250.0
BCVA improvement of >= 5 lettersmonth 2483.389.370.0
BCVA improvement of >= 10 lettersmonth 666.768.541.1
BCVA improvement of >= 10 lettersmonth 2471.175.860.0
BCVA improvement of >= 15 lettersmonth 645.047.227.8
BCVA improvement of >= 15 lettersmonth 2452.859.643.3
BCVA improvement of >= 30 lettersmonth 610.09.63.3
BCVA improvement of >= 30 lettersmonth 2413.314.011.1
SecondaryNumber of Patients With a BCVA Improvement vs Baseline or Achieving Greater Than or Equal to 73 Letters at Month 6 in the Study Eye

Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and Month 6 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 6 indicates a positive outcome.

Time frame:
Month 6
Reported as:
Number · participants
Number of Patients With a BCVA Improvement vs Baseline or Achieving Greater Than or Equal to 73 Letters at Month 6 in the Study Eye
participants1-ranibizumab Monotherapy2-ranibizumab With Laser3-laser Monotherapy
BCVA improvement of ≥ 1 letter16817157
BCVA improvement of ≥ 5 letters N15515745
BCVA improvement of ≥ 10 letters12012237
BCVA improvement of ≥ 15 letters818425
BCVA improvement of ≥ 30 letters18173
BCVA score ≥ 73 letters1189728
SecondaryNumber of Patients With a BCVA Improvement vs Baseline or Achieved Greater Than or Equal to 73 Letters at Month 24 in the Study Eye

Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and Month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 24 indicates a positive outcome.

Time frame:
Month 24
Reported as:
Number · participants
Number of Patients With a BCVA Improvement vs Baseline or Achieved Greater Than or Equal to 73 Letters at Month 24 in the Study Eye
participants1-ranibizumab Monotherapy2-ranibizumab With Laser3-laser Monotherapy
BCVA improvement of ≥ 1 letter16116770
BCVA improvement of ≥ 5 letters15015963
BCVA improvement of ≥ 10 letters12913554
BCVA improvement of ≥ 15 letters9510639
BCVA improvement of ≥ 30 letters242510
BCVA score ≥ 73 letters11911441
SecondaryThe Mean Change in Central Reading Center-assessed Central Subfield Thickness From Month 12 and Month 24 vs. Baseline by Treatment Arm

Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation. Stratification was done based on categories of baseline best corrected visual acuity \& analysis was based on analysis of variance (ANOVA)

Time frame:
Month 12 and Month 24
Reported as:
Mean · microns
The Mean Change in Central Reading Center-assessed Central Subfield Thickness From Month 12 and Month 24 vs. Baseline by Treatment Arm
microns1-ranibizumab Monotherapy2-ranibizumab With Laser3-laser Monotherapy
month 12-215.9 ± 12.83-242.5 ± 14.14-203.9 ± 22.22
month 24-228.1 ± 12.65-261.7 ± 15.20-232.7 ± 24.38
SecondaryThe Mean Change in Patient Reported Outcomes in NEI-VFQ-25 Score (Composite Score and Subscales) at Month 6 and Month 24 Compared to Baseline

The survey consists of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.

Time frame:
Months 6 and 24
Reported as:
Mean · score on a scale
The Mean Change in Patient Reported Outcomes in NEI-VFQ-25 Score (Composite Score and Subscales) at Month 6 and Month 24 Compared to Baseline
score on a scale1-ranibizumab Monotherapy2-ranibizumab With Laser3-laser Monotherapy
month 6 composite score5.6 ± 9.564.2 ± 10.413.7 ± 12.12
month 24 composite score8.0 ± 11.785.0 ± 11.444.9 ± 14.79
SecondaryBCVA (Letters) Mean Average Change From First Ranibizumab Treatment to Month 24 in the Study Eye for Patients Randomized to the Laser Monotherapy Arm

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 24 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and assessed by an ANOVA model.

Time frame:
Month 24
Reported as:
Mean · BCVA letters
BCVA (Letters) Mean Average Change From First Ranibizumab Treatment to Month 24 in the Study Eye for Patients Randomized to the Laser Monotherapy Arm
BCVA letters3- Laser Monotherapy
Value at 1st Ranibizumab treatment61.7 ± 12.21
Average post 1st treatment through Month 2468.16 ± 11.84
Change from 1st Ranibizumab treatment6.49 ± 7.83

Adverse events

Collected over [1] Safety set was summarized based on actual treatment received. There were 3 laser monotherapy patients who received ranibizumab and 1 ranibizumab patient who received laser treatment which resulted in percentages > 100% for the ranibizumab + laser arm.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5mg—30/180 (16.7%)112/180 (62.2%)
Ranibizumab 0.5mg + Laser—33/183 (18%)121/183 (66.1%)
Laser Monotherapy With Ranibizumab 0.5 mg From Month 6—10/63 (15.9%)40/63 (63.5%)
Laser Monotherapy Without Ranibizumab 0.5 mg From Month 6—3/25 (12%)14/25 (56%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventRanibizumab 0.5mgRanibizumab 0.5mg + LaserLaser Monotherapy With Ranibizumab 0.5 mg From Month 6Laser Monotherapy Without Ranibizumab 0.5 mg From Month 6
Gallbladder disorderHepatobiliary disorders1/1800/1830/631/25
PneumoniaInfections and infestations0/1801/1830/631/25
Hip fractureInjury, poisoning and procedural complications0/1800/1830/631/25
Atrial fibrillationCardiac disorders3/1801/1830/630/25
Angina pectorisCardiac disorders0/1800/1831/630/25
ArrhythmiaCardiac disorders0/1800/1831/630/25
Atrioventricular block second degreeCardiac disorders1/1800/1831/630/25
Cardiac arrestCardiac disorders0/1800/1831/630/25
Macular fibrosis (Study eye)Eye disorders0/1800/1831/630/25
Lower respiratory tract infectionInfections and infestations1/1800/1831/630/25
Most frequent other events
Showing 10 of 87
Most frequent other events
EventRanibizumab 0.5mgRanibizumab 0.5mg + LaserLaser Monotherapy With Ranibizumab 0.5 mg From Month 6Laser Monotherapy Without Ranibizumab 0.5 mg From Month 6
HypertensionVascular disorders19/18022/1837/632/25
Eye pain (Study eye)Eye disorders18/18021/1833/630/25
HeadacheNervous system disorders11/1809/1836/630/25
Intraocular pressure increased (Study eye)Investigations17/18017/1832/630/25
NasopharyngitisInfections and infestations15/18017/1834/631/25
Conjunctival haemorrhage (Study eye)Eye disorders15/18015/1835/630/25
Ocular hypertension (Study eye)Eye disorders5/1804/1830/632/25
Back painMusculoskeletal and connective tissue disorders5/1808/1831/632/25
InfluenzaInfections and infestations13/18013/1832/631/25
Visual acuity reduced (Study eye)Eye disorders5/1806/1834/631/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)1-ranibizumab Monotherapy2-ranibizumab With Laser3-laser MonotherapyTotal
Mean64.7 ± 10.3467.3 ± 10.4167.7 ± 9.6766.3 ± 10.30
Sex: Female, Male
Sex: Female, Male(Participants)1-ranibizumab Monotherapy2-ranibizumab With Laser3-laser MonotherapyTotal
Female908455229
Male939637226
08

Study locations

82 sites
  • Novartis Investigative Site
    Parramatta, New South Wales 2150, Australia
  • Novartis Investigative Site
    Sydney, New South Wales 2000, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3002, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    Calgary, Alberta T2H0C8, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novartis Investigative Site
    Victoria, British Columbia V8V 4X3, Canada
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Novartis Investigative Site
    London, Ontario N6A 4G5, Canada
  • Novartis Investigative Site
    Boisbriand, Quebec J7H 1S6, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Olomouc, 775 20, Czech Republic
  • Novartis Investigative Site
    Praha 10, 100 34, Czech Republic
  • Novartis Investigative Site
    Glostrup, DK-2600, Denmark
  • Novartis Investigative Site
    Dijon, 21033, France
  • Novartis Investigative Site
    Lyon, 69003, France
  • Novartis Investigative Site
    Nice, 06000, France
  • Novartis Investigative Site
    Paris cedex 10, 75010, France
  • Novartis Investigative Site
    Paris Cedex 19, 75940, France
  • Novartis Investigative Site
    Paris, France
  • Novartis Investigative Site
    Athens, GR 124 62, Greece
  • Novartis Investigative Site
    Heraklion Crete, GR 711 10, Greece
  • Novartis Investigative Site
    Larissa, GR 411 10, Greece
  • Novartis Investigative Site
    Thessaloniki, GR 546 29, Greece
  • Novartis Investigative Site
    Patras, 26504, Greece
  • Novartis Investigative Site
    Thessaloniki, GR 54636, Greece
  • Novartis Investigative Site
    Budapest, 1133, Hungary
  • Novartis Investigative Site
    Budapest, H-1083, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Dublin 7, Ireland
  • Novartis Investigative Site
    Dublin, Ireland
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Milano, MI 20100, Italy
  • Novartis Investigative Site
    Milano, MI 20132, Italy
  • Novartis Investigative Site
    Roma, RM 00144, Italy
  • Novartis Investigative Site
    Torino, TO 10122, Italy
  • Novartis Investigative Site
    Bari, 70124, Italy
  • Novartis Investigative Site
    Udine, 33100, Italy
  • Novartis Investigative Site
    Leiden 2333 ZA, 2333, Netherlands
  • Novartis Investigative Site
    Rotterdam, 3011 BH, Netherlands
  • Novartis Investigative Site
    Tilburg, 5022 GC, Netherlands
  • Novartis Investigative Site
    Bielsko-Biala, 43-300, Poland
  • Novartis Investigative Site
    Gdansk, 80-809, Poland
  • Novartis Investigative Site
    Kraków, 31-501, Poland
  • Novartis Investigative Site
    Lublin, 20-079, Poland
  • Novartis Investigative Site
    Warszawa, 02-005, Poland
  • Novartis Investigative Site
    Wroclaw, 50-556, Poland
  • Novartis Investigative Site
    Coimbra, 3000-354, Portugal
  • Novartis Investigative Site
    Coimbra, 3030-163, Portugal
  • Novartis Investigative Site
    Lisboa, 1050-085, Portugal
  • Novartis Investigative Site
    Lisboa, 1349-019, Portugal
  • Novartis Investigative Site
    Porto, 4099-001, Portugal
  • Novartis Investigative Site
    Porto, 4200-319, Portugal
  • Novartis Investigative Site
    Zilina, Slovak Republic 010 01, Slovakia
  • Novartis Investigative Site
    Banska Bystrica, 975 17, Slovakia
  • Novartis Investigative Site
    Bratislava, 826 06, Slovakia
  • Novartis Investigative Site
    Bratislava, 851 07, Slovakia
  • Novartis Investigative Site
    Valladolid, Castilla y Leon 47011, Spain
  • Novartis Investigative Site
    Barcelona, Cataluña 08022, Spain
  • Novartis Investigative Site
    Barcelona, Cataluña, Spain
  • Novartis Investigative Site
    L´Hospitalet de Llobregat, Cataluña 08907, Spain
  • Novartis Investigative Site
    Alicante, Comunidad Valenciana 03016, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46014, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46015, Spain
  • Novartis Investigative Site
    Santiago de Compostela, Galicia 15706, Spain
  • Novartis Investigative Site
    Bilbao, Pais Vasco 48006, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Örebro, 701 85, Sweden
  • Novartis Investigative Site
    Bern, 3012, Switzerland
  • Novartis Investigative Site
    Lausanne, 1007, Switzerland
  • Novartis Investigative Site
    Olten, 4600, Switzerland
  • Novartis Investigative Site
    Zuerich, 8063, Switzerland
  • Novartis Investigative Site
    Frimley, Surrey GU16 7UJ, United Kingdom
  • Novartis Investigative Site
    Belfast, BT12 6BA, United Kingdom
  • Novartis Investigative Site
    Birmingham, B9 5SS, United Kingdom
  • Novartis Investigative Site
    Bristol, BS1 2LX, United Kingdom
  • Novartis Investigative Site
    London, EC1V 2PD, United Kingdom
  • Novartis Investigative Site
    London, NW1 5QH, United Kingdom
  • Novartis Investigative Site
    Newcastle upon Tyne, NE1 4LP, United Kingdom
  • Novartis Investigative Site
    Plymouth, PL4 6PL, United Kingdom
  • Novartis Investigative Site
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Pawloff M, Bogunovic H, Gruber A, Michl M, Riedl S, Schmidt-Erfurth U. SYSTEMATIC CORRELATION OF CENTRAL SUBFIELD THICKNESS WITH RETINAL FLUID VOLUMES QUANTIFIED BY DEEP LEARNING IN THE MAJOR EXUDATIVE MACULAR DISEASES. Retina. 2022 May 1;42(5):831-841. doi: 10.1097/IAE.0000000000003385. PubMed 34934034 ↗
  • Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, Das Gupta A, Wenzel A, Pearce I; BRIGHTER Study Group. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study. Ophthalmology. 2017 Dec;124(12):1778-1787. doi: 10.1016/j.ophtha.2017.06.027. Epub 2017 Aug 12. Erratum In: Ophthalmology. 2018 Mar;125(3):463. doi: 10.1016/j.ophtha.2017.12.012. PubMed 28807635 ↗
  • Tadayoni R, Waldstein SM, Boscia F, Gerding H, Pearce I, Priglinger S, Wenzel A, Barnes E, Gekkieva M, Pilz S, Mones J; BRIGHTER study group. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER. Ophthalmology. 2016 Jun;123(6):1332-44. doi: 10.1016/j.ophtha.2016.02.030. Epub 2016 Mar 30. PubMed 27039022 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2012
First posted
May 16, 2012
Start
May 2012
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Nov 10, 2016
Last update
Nov 10, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01599650
Responsible party
Sponsor
First posted
May 16, 2012
Start date
May 2012
Primary completion
May 2015
Completion
May 2015
Results posted
Nov 10, 2016
Last update
Nov 10, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion